Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mitchell

Showing results (1351-1360 of 1,365) with videos related to

Pageof 137
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialS Peters, J-L Pujol, U Dafni, et al.
Nature Medicine|June 15, 2023
The NCI-MATCH trial: lessons for precision oncologyPeter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Plos One|April 15, 2022
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithmsTinsay A Woreta, Mark L Van Natta, Mariana Lazo, et al.
JCO Precision Oncology|February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol IIan E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
The New England Journal of Medicine|January 18, 2023
Futibatinib for <i>FGFR2</i>-Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, et al.
The EMBO Journal|August 27, 2020
Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2Theresa Klemm, Gregor Ebert, Dale J Calleja, et al.
NPJ Precision Oncology|March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialA S Mansfield, Z Wei, R Mehra, et al.
The Oncologist|December 20, 2019
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)A Bapsi Chakravarthy, Fengmin Zhao, Neal J Meropol, et al.
Journal of the National Cancer Institute|January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial DesignKeith T Flaherty, Robert Gray, Alice Chen, et al.
Journal of Environmental Quality|May 22, 2025
The key role of local and global farmer networks in the development of conservation agriculture in CaliforniaJ P Mitchell, L E Jackson, D C Reicosky, et al.
Pageof 137

Showing results (1351-1360 of 1,365) with videos related to

Sort By:
Pageof 137
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialS Peters, J-L Pujol, U Dafni, et al.
Nature Medicine|June 15, 2023
The NCI-MATCH trial: lessons for precision oncologyPeter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Plos One|April 15, 2022
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithmsTinsay A Woreta, Mark L Van Natta, Mariana Lazo, et al.
JCO Precision Oncology|February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol IIan E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
The New England Journal of Medicine|January 18, 2023
Futibatinib for <i>FGFR2</i>-Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, et al.
The EMBO Journal|August 27, 2020
Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2Theresa Klemm, Gregor Ebert, Dale J Calleja, et al.
NPJ Precision Oncology|March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialA S Mansfield, Z Wei, R Mehra, et al.
The Oncologist|December 20, 2019
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)A Bapsi Chakravarthy, Fengmin Zhao, Neal J Meropol, et al.
Journal of the National Cancer Institute|January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial DesignKeith T Flaherty, Robert Gray, Alice Chen, et al.
Journal of Environmental Quality|May 22, 2025
The key role of local and global farmer networks in the development of conservation agriculture in CaliforniaJ P Mitchell, L E Jackson, D C Reicosky, et al.
Pageof 137